IMMUPHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.165 GBX | +6.91% |
|
+13.95% | +29.87% |
| Apr. 29 | Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director | CI |
| Apr. 02 | Immupharma jumps amid new IP strategy for P140 technology platform | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 118K 148K | Sales 2022 | - | Capitalization | 6.13M 7.68M |
|---|---|---|---|---|---|
| Net income 2021 | -8M -10.02M | Net income 2022 | -3M -3.76M | EV / Sales 2021 | 126 x |
| Net cash position 2021 | 1.65M 2.06M | Net cash position 2022 | 668K 836K | EV / Sales 2022 | - |
| P/E ratio 2021 |
-2.03
x | P/E ratio 2022 |
-1.46
x | Employees | 13 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +6.91% | ||
| 1 week | +13.95% | ||
| Current month | +1.88% | ||
| 1 month | -11.63% | ||
| 3 months | +65.65% | ||
| 6 months | +26.61% | ||
| Current year | +29.87% |
1 week
1.80
2.29
1 month
1.802.66
Current year
0.823.00
1 year
0.823.80
3 years
0.8210.90
5 years
0.8232.20
10 years
0.82193.74
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 15-09-29 | |
Timothy Franklin
COO | Chief Operating Officer | 60 | 20-10-31 |
Lisa Baderoon
BRD | Director/Board Member | 57 | 12-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 68 | 15-09-29 | |
Timothy Franklin
COO | Chief Operating Officer | 60 | 20-10-31 |
Lisa Baderoon
BRD | Director/Board Member | 57 | 12-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 2.165 | +6.91% | 4,381,830 |
| 24-05-09 | 2.025 | -2.41% | 1,332,281 |
| 24-05-08 | 2.075 | +2.72% | 1,046,404 |
| 24-05-07 | 2.02 | +6.32% | 2,307,592 |
| 24-05-03 | 1.9 | -6.86% | 1,925,128 |
Delayed Quote London S.E., May 10, 2024 at 11:35 am EDT
More quotes
ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.
Calendar
2024-05-11
- BIO Equity Conference
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +29.87% | 11.28M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- IMM Stock